Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.52 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560655 | 0.86 | ADRA2A (0.55) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL560777 | 0.85 | LMNA (0.56) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| Iodide SCHEMBL16227866 | 0.84 | LMNA (0.59) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8148008 | 0.83 | LMNA (0.52) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL560745 | 0.83 | LMNA (0.55) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8133645 | 0.83 | SMN1; SMN2 (0.50) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL20017860 | 0.78 | SMN1; SMN2 (0.50) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL561403 | 0.78 | LMNA (0.62) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8139996 | 0.78 | HTR1D (0.52) | ADRA2ALMNAADRA2BADRA2CADRA1D | |
| SCHEMBL8148018 | 0.77 | LMNA (0.46) | ADRA2ALMNAADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2932968-B1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-01-17 | — | — | EP | claimed |
| EP-2932968-A1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2015-10-21 | — | — | EP | claimed |
| EP-2303264-B1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES | ALLERGAN INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2932968-B1 | COMPOUND FOR TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9849113-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623006-B2 | Methods of treating α adrenergic mediated conditions | ALLERGAN, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-8071636-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063231-B2 | Methods of treating alpha adrenergic mediated conditions | ALLERGAN, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2009152053-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATES | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009152052-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885LMNA 1467/4885ADRA2B 7/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | ADRA2A 3/4885LMNA 1467/4885ADRA2B 7/4885 |
| US-20170172982-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
| US-20180071260-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | ADRA2A 2/4885LMNA 1464/4885ADRA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.